Last reviewed · How we verify
Bromfenac eye drop
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. Used for Postoperative inflammation and pain following ocular surgery, Ocular itching associated with allergic conjunctivitis.
At a glance
| Generic name | Bromfenac eye drop |
|---|---|
| Also known as | Yellox |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, bromfenac decreases production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. As a topical ophthalmic formulation, it achieves high local concentrations while minimizing systemic exposure.
Approved indications
- Postoperative inflammation and pain following ocular surgery
- Ocular itching associated with allergic conjunctivitis
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Corneal erosion or delayed epithelialization
- Headache
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromfenac eye drop CI brief — competitive landscape report
- Bromfenac eye drop updates RSS · CI watch RSS
- Azienda USL Reggio Emilia - IRCCS portfolio CI